Catheter-directed thrombolysis sales will grow through 2036, led by direct delivery to blood clot at a 68.0% share in 2026 as the leading delivery mode segment. The market is expected to reach USD 540.09 million in 2026 and USD 958.13 million by 2036, creating an absolute opportunity of USD 418.04 million.